MILLENDO THERAPEUTICS Revenue and Competitors
Estimated Revenue & Valuation
- MILLENDO THERAPEUTICS's estimated annual revenue is currently $775k per year.
- MILLENDO THERAPEUTICS's estimated revenue per employee is $77,500
- MILLENDO THERAPEUTICS's total funding is $116.5M.
- MILLENDO THERAPEUTICS has 10 Employees.
- MILLENDO THERAPEUTICS grew their employee count by -76% last year.
MILLENDO THERAPEUTICS Competitors & Alternatives
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is MILLENDO THERAPEUTICS?
Millendo Therapeutics is focused on developing novel treatments for endocrine diseases. Our mission is to build a leading endocrine company that creates distinct and transformative treatments for a wide range of diseases where there is a significant unmet medical need. We are currently advancing two product candidates: livoletide (AZP-531) and nevanimibe (ATR-101). Livoletide is being developed for Prader-Willi syndrome while nevanimibe is in development for the treatment of two different orphan adrenal diseases: Classic Congenital Adrenal Hyperplasia (CAH) and Endogenous Cushing's Syndrome (CS).keywords:Licensing,Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
MILLENDO THERAPEUTICS News
Millendo Therapeutics. Levo Therapeutics. Harmony Biosciences. Soleno Therapeutics. And many more. Prader-Willi Syndrome Therapies covered in...
Zynerba Pharmaceuticals (NASDAQ:ZYNE) and Millendo Therapeutics (NASDAQ:MLND) are both small-cap medical companies, but which is ...
ANN ARBOR, Mich.--(BUSINESS WIRE)--. Millendo Therapeutics, Inc. (MLND), a clinical-stage biopharmaceutical company developing novel ...
Millendo Therapeutics, Inc. (MLND), a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for orphan ...
Share Share on Facebook Share on Twitter LinkedIn Email Reprints —Millendo Therapeutics, an Ann Arbor-based biopharmaceutical company developing treatments for rare diseases, has initiated a Phase 2b/3 clinical study investigating livoletide (AZP-531) in patients with Prader-Willi syndrome. Th ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|